160 related articles for article (PubMed ID: 37737688)
1. Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
D'Anniballe VM; Huang MN; Lueck BD; Nicholson LT; McFatridge I; Gunn MD
J Immunother; 2023 Nov-Dec 01; 46(9):333-340. PubMed ID: 37737688
[TBL] [Abstract][Full Text] [Related]
2. Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Zheng F; Dang J; Zhang H; Xu F; Ba D; Zhang B; Cheng F; Chang AE; Wicha MS; Li Q
J Immunother; 2018 Oct; 41(8):361-368. PubMed ID: 30063587
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
4. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Curran MA; Allison JP
Cancer Res; 2009 Oct; 69(19):7747-55. PubMed ID: 19738077
[TBL] [Abstract][Full Text] [Related]
5.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
6. Monocytes as a Cellular Vaccine Platform to Induce Antitumor Immunity.
Huang MN; D'Anniballe VM; Gunn MD
Methods Mol Biol; 2022; 2410():627-647. PubMed ID: 34914073
[TBL] [Abstract][Full Text] [Related]
7. Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.
Huang MN; Nicholson LT; Batich KA; Swartz AM; Kopin D; Wellford S; Prabhakar VK; Woroniecka K; Nair SK; Fecci PE; Sampson JH; Gunn MD
J Clin Invest; 2020 Feb; 130(2):774-788. PubMed ID: 31661470
[TBL] [Abstract][Full Text] [Related]
8. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
9. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy.
Zahm CD; Moseman JE; Delmastro LE; G Mcneel D
Oncoimmunology; 2021 Apr; 10(1):1912892. PubMed ID: 33996265
[TBL] [Abstract][Full Text] [Related]
11. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
13. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8
Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K
Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728
[No Abstract] [Full Text] [Related]
14. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
15. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
16. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
[TBL] [Abstract][Full Text] [Related]
18. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
[TBL] [Abstract][Full Text] [Related]
19. Human CD141
Lee YS; O'Brien LJ; Walpole CM; Pearson FE; Leal-Rojas IM; Masterman KA; Atkinson V; Barbour A; Radford KJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737342
[TBL] [Abstract][Full Text] [Related]
20. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
